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Abstract
Objective
SYNTAX score II (SSII) is a long-term mortality prediction model to guide the decision mak-
ing of the heart-team between coronary artery bypass grafting or percutaneous coronary
intervention (PCI) in patients with left main or three-vessel coronary artery disease. This
study aims to investigate the long-term predictive value of SSII for all-cause mortality in
patients with one- or two-vessel disease undergoing PCI.
Methods
A total of 628 patients (76% men, mean age: 61±10 years) undergoing PCI due to stable
angina pectoris (43%) or acute coronary syndrome (57%), included between January 2008
and June 2013, were eligible for the current study. SSII was calculated using the original
SYNTAX score website (www.syntaxscore.com). Cox regression analysis was used to
assess the association between continuous SSII and long-term all-cause mortality. The
area under the receiver-operating characteristic curve was used to assess the performance
of SSII.
Results
SSII ranged from 6.6 to 58.2 (median: 20.4, interquartile range: 16.1–26.8). In multivariable
analysis, SSII proved to be an independent significant predictor for 4.5-year mortality (haz-
ard ratio per point increase: 1.10; 95% confidence interval: 1.07–1.13; p<0.001). In terms of
discrimination, SSII had a concordance index of 0.77.
Conclusion
In addition to its established value in patients with left main and three-vessel disease, SSII
may also predict long-term mortality in PCI-treated patients with one- or two-vessel disease.
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Introduction
The SYNTAX score II (SSII) has been established as a long-term mortality prediction model to
guide the decision making of the heart-team between coronary artery bypass grafting (CABG)
or percutaneous coronary intervention (PCI) in patients with complex coronary artery disease
(CAD).[1] It combines the original anatomical-based SYNTAX score, which grades the com-
plexity of CAD in all coronary arteries, with the clinical baseline variables that have shown to
be important predictors of 4-year all-cause mortality in the SYNTAX trial.[1]
SSII has been validated in large patient cohorts with left main or three-vessel disease.[1–3]
However, the predictive performance of SSII on long-term mortality in patients with less com-
plex CAD is currently unknown.
This study aims to investigate the long-term predictive value of SSII for all-cause mortality
in patients with one- or two-vessel disease undergoing PCI.
Methods
Study design and population
This study combines the populations of The European Collaborative Project on Inflammation
and Vascular Wall Remodeling in Atherosclerosis-intravascular ultrasound (ATHERORE-
MO-IVUS) study and the Integrated Biomarker and Imaging Study-3 (IBIS-3).[4, 5] Study
designs and methods of ATHEROREMO-IVUS and IBIS-3 have been described in detail else-
where.[4, 5] Baseline study procedures and inclusion criteria were similar and both studies
were conducted at the Erasmus Medical Center, Rotterdam, The Netherlands. In brief, patients
undergoing diagnostic coronary angiography (CAG) or PCI for an acute coronary syndrome
(ACS) or stable angina pectoris (SAP) were included. During CAG, invasive imaging was per-
formed in one non-culprit coronary artery segment. Subsequently, patients were followed-up
on adverse cardiovascular events. Patient care was left at the discretion of the physician. Dur-
ing the first year after the index procedure, as per protocol, patients included in IBIS-3
received high dose rosuvastatin.
The medical ethics committee of the Erasmus MC approved both the ATHEROREMO-I-
VUS and IBIS-3 study. Both studies were performed in accordance with the declaration of Hel-
sinki. All patients provided written informed consent for their participation in these studies,
and compliance with the study protocols, including long-term follow-up. The ATHERORE-
MO-IVUS study is registered in ClinicalTrials.gov, number NCT01789411, and the IBIS-3
study is registered in The Netherlands trial register, number NTR2872.
SYNTAX score II
The anatomical-based SYNTAX score was determined (pre-PCI) for every coronary angio-
gram taken at study entry, by a trained analyst blinded for patient characteristics and outcome
using the SYNTAX Score Calculator (www.syntaxscore.com). The calculation of the anatomi-
cal-based SYNTAX score has been described in detail previously.[6] In brief, the complete cor-
onary tree is divided in 16 segments and assessed for lesions producing 50% or more luminal
obstruction. Every segment has a pre-specified corresponding weighing factor which, in case
of a significant lesion, is added to the SYNTAX score by the SYNTAX Score Calculator. More-
over, other variables (i.e. calcification or lesion length) that reflect the complexity of a patient’s
CAD and, thus, the complexity of treatment are assessed and taken into account in the SYN-
TAX score. Eventually, the SYNTAX score is composed of these total points summed, and
reflects the complexity of a patient’s CAD. As previously applied in other all-comers and ST-
segment elevation myocardial infarction (STEMI) populations, lesions caused by in-stent
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restenosis were treated as de novo lesions.[7–9] Total occlusions were scored as occlusions of
unknown duration, as the analyst was blinded for all patient information.[10]
Subsequently, data on the baseline variables age, gender, creatinine clearance (CRCL), left
ventricular ejection fraction (LVEF), peripheral vascular disease and chronic obstructive pul-
monary disease was collected for the calculation of SSII. We used the original SYNTAX Score
II Calculator (www.syntaxscore.com) to obtain all SSII values. The algorithm of the SSII calcu-
lation has been described in detail elsewhere.[1]
Study endpoint
The primary endpoint was all-cause mortality. Vital status of the patients was obtained from
municipal civil registries.
Statistical analysis
The distribution of continuous variables was examined for normality with the Kolmogorov-
Smirnov test. ANOVA or Kruskal-Wallis test were used for multiple group comparison of con-
tinuous variables. Categorical variables were compared using the Pearson Chi-square test.
Data for most of the variables used for the calculation of SSII were complete. However, cre-
atinine, required for the calculation of CRCL, was available in 92.8% of the patients. LVEF was
available in 72.0% of the patients and categorized as good (LVEF50%), moderate (LVEF 40–
49%) and poor (LVEF<40%).[11] Because LVEF was reported qualitatively, a value of 50%
was used for category good, 44.5% for category moderate and 35% for category poor for the
calculation of SSII. Multiple imputation technique was used to impute the missing data of cre-
atinine and LVEF. Ten imputed data sets were generated. Analyses were conducted for both
the complete dataset as the imputed datasets, which showed similar results.
Long-term cumulative incidences of all-cause mortality, categorized by SSII in tertiles, were
compared with the log-rank test. Cox regression analysis was used to assess the association
between continuous SSII and long-term all-cause mortality. Patients that were lost to follow-
up were censored at the date of last contact. Based on existing literature, variables known to be
associated with mortality and not part of the SSII (diabetes mellitus, hypertension, smoking,
previous PCI and indication for coronary angiography) were entered in a multivariable Cox
model. Since our study population also includes STEMI-patients and the use of SSII has been
validated in stable patients, a subgroup analysis was performed in patients with SAP only, to
compare the results of the total study population with the results found in patients with SAP
only. In terms of discrimination, the area under the receiver-operating characteristic (ROC)
curve was assessed. All statistical test were two-sided with a type I error level of 0.05. Analyses
were performed with IBM SPSS Statistics version 21.0.
Results
A total of 628 patients (76% men, mean age: 61 ±10 years) undergoing PCI due to SAP (43%)
or ACS (57%), included between January 2008 and June 2013, were eligible for the current
study (Table 1). SSII ranged from 6.6 to 58.2 (median: 20.4, IQR: 16.1–26.8). All-cause mortal-
ity occurred in 44 patients (7.0%) during a median follow-up of 4.5 (IQR: 3.4–4.9) years.
Patients with a high SSII were older, had a higher prevalence of diabetes mellitus, hyperten-
sion, hypercholesterolemia and COPD, and more frequently had a history of renal insuffi-
ciency or heart failure than patients with a mid or low SSII.
Cumulative incidence of all-cause mortality categorized by SSII in tertiles is shown in Fig 1.
The long-term cumulative incidence of all-cause mortality of patients with a high SSII showed
to be significantly higher than for patients with a mid or low SSII. No statistically significant
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difference was found between the cumulative incidence of all-cause mortality of patients with
a mid versus low SSII value.
In the multivariable Cox model (Table 2), SSII proved to be an independent significant pre-
dictor for 4.5-year mortality (hazard ratio [HR] per point increase: 1.10; 95% confidence inter-
val [CI]: 1.07–1.13). For SAP patients only, results were similar to the total study population
(HR: 1.06; 95%CI: 1.07–1.11). In terms of discrimination, SSII had a concordance index (c-
index) of 0.77 (95%CI: 0.69–0.84) (Fig 2).
Discussion
In this study, we validated for the first time the use of SSII for prediction of long-term mortal-
ity in a large PCI-treated patient population with one- or two-vessel disease. SSII demonstrated
to be an independent predictor for 4.5-year all-cause mortality in multivariable analysis. More-
over, in terms of discrimination, SSII had a c-index of 0.77 which is in line with the internally
and externally validated c-indices of 0.73 and 0.72, respectively, of SSII in the SYNTAX trial
Table 1. Baseline characteristics.
Clinical characteristics SSII17 (n = 209) 17< SSII24 (n = 210) SSII >24 (n = 209) p value
Age—yrs, ± sd 52.9 ± 7.8 61.5 ± 8.1 69.0 ± 9.2 <0.001
Men, n (%) 204 (97.6) 163 (77.6) 109 (52.2) <0.001
Diabetes mellitus, n (%) 28 (13.4) 40 (19.0) 49 (23.4) 0.051
Hypertension, n (%) 91 (34.5) 112 (53.3) 134 (64.1) <0.001
Hypercholesterolemia, n (%) 96 (45.9) 120 (57.1) 127 (60.8) 0.025
Current smoking, n (%) 88 (42.3) 60 (28.6) 47 (22.5) <0.001
Previous MI, n (%) 55 (26.3) 57 (27.1) 64 (30.6) 0.48
Previous PCI, n (%) 58 (27.8) 65 (31.0) 60 (28.7) 0.74
Previous CVA, n (%) 10 (4.8) 10 (4.8) 18 (8.6) 0.16
History of PAD, n (%) 0 (0.0) 0 (0.0) 46 (22.0) <0.001
History of renal insufficiency, n (%) 6 (2.9) 4 (1.9) 20 (9.6) <0.001
History of heart failure, n (%) 1 (0.5) 2 (1.0) 10 (4.8) 0.003
COPD, n (%) 1 (0.5) 9 (4.3) 23 (11.0) <0.001
Serum creatinine—μmol/L, ± sd 77.3 ± 13.2 74.8 ± 17.3 84.6 ± 28.3 <0.001
Creatinine clearance—ml/min, ± sd 127.8 ± 31.8 111.9 ± 34.3 80.1 ± 27.8 <0.001
LVEF, n (%) <0.001
Good LVEF50% 189 (90.4) 156 (74.2) 136 (65.1)
Moderate LVEF 40–49% 20 (9.6) 54 (25.8) 65 (31.1)
Poor LVEF <40% 0 (0.0) 0 (0.0) 8 (3.8)
Angiographic characteristics
Indication for angiography, n (%) 0.16
Acute MI 77 (36.8) 64 (30.6) 51 (24.4)
Unstable angina 58 (27.8) 57 (27.3) 61 (29.2)
Stable angina 74 (35.4) 99 (47.4) 97 (46.4)
Coronary artery disease, n (%) 0.007
1-vessel disease 146 (69.9) 118 (56.5) 115 (55.0)
2-vessel disease 63 (30.1) 92 (43.5) 94 (45.0)
Median SS [IQR] 5.0 [3.0–9.0] 9.0 [5.0–13.5] 9.0 [5.0–15.0] <0.001
CI: confidence interval; COPD: Chronic obstructive pulmonary disease; CVA: Cerebrovascular accident; IQR: inter quartile range; LVEF: left ventricular ejection
fraction; MI: Myocardial infarction; PAD: Peripheral artery disease; PCI: Percutaneous coronary intervention; sd: standard deviation; SS: SYNTAX score; SSII: SYNTAX
score II; yrs: years.
https://doi.org/10.1371/journal.pone.0200076.t001
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Fig 1. Cumulative incidence of all-cause mortality at 4.5 years. SSII is divided in tertiles with cut-off points 17 and
24 to compare the cumulative all-cause mortality proportions between patients with a low, mid or high SSII value. SSII:
Syntax score II.
https://doi.org/10.1371/journal.pone.0200076.g001
Table 2. Prediction of long-term mortality.
Total population (n = 628) SAP patients only (n = 270)
Unadjusted HR (95%CI) p value Unadjusted HR (95%CI) p value
SSII 1.09 (1.07–1.12) <0.001 SSII 1.05 (1.00–1.10) 0.050
Adjusted HR (95%CI) Adjusted HR (95%CI)
SSII 1.10 (1.07–1.13) <0.001 SSII 1.06 (1.07–1.11) 0.037
Smoking 1.01 (0.52–1.98) 0.97 Smoking 1.52 (0.48–4.82) 0.48
Diabetes mellitus 1.60 (0.79–3.24) 0.19 Diabetes mellitus 1.56 (0.52–4.62) 0.43
Hypertension 0.88 (0.46–1.68) 0.70 Hypertension 0.59 (0.21–1.71) 0.33
Previous PCI 1.09 (0.54–2.18) 0.82 Previous PCI 0.59 (0.20–1.75) 0.35
Indication for CAG, SAP 0.59 (0.30–1.15) 0.12
SSII incorporates the anatomical Syntax score, age, gender, creatinine clearance, left ventricular ejection fraction, peripheral vascular disease and chronic obstructive
pulmonary disease
CAG: coronary angiography; CI: confidence interval; HR: hazard ratio; PCI: percutaneous coronary intervention; SAP: stable angina pectoris; SSII: Syntax score II
https://doi.org/10.1371/journal.pone.0200076.t002
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for CABG or PCI-treated patients with left main or three-vessel disease.[1] It is also in line
with the c-index (0.75) of SSII found in a study of patients with left main or three-vessel disease
treated with only PCI.[3]
Although other known predictors of all-cause mortality in patients with CAD which are
not part of SSII, such as diabetes mellitus, hypertension and prior PCI, were entered in the
multivariable Cox model, SSII demonstrated to be the only significant predictor for 4.5-year
all-cause mortality. Diabetes mellitus is a well-known predictor for adverse outcome in
patients treated with PCI.[12] However, our findings imply that SSII incorporates enough rele-
vant clinical prognostic variables to predict long-term all-cause mortality in patients with one-
or two-vessel disease. Recently, the performance of SSII has been compared in diabetic patients
versus non-diabetic patients with multi-vessel or left main disease undergoing PCI.[13] The
SSII showed to have a good discriminative ability in both patient groups, independent of dia-
betic status. It may be hypothesized that other clinical variables incorporated in the SSII, such
as CRCL, sufficiently reflect the influence of diabetes mellitus. In this respect, a previous study
has demonstrated that kidney disease is of greater importance than diabetes mellitus for risk
prediction of adverse outcome in patients with CAD.[14]
SSII has been developed for individual risk assessment using a continuous scale to over-
come the limitations of categorized risk scores. Our study validates the use of SSII in patients
with one- or two-vessel disease, demonstrating a similar discrimination as previously reported
in left main or three-vessel disease.
Limitations
In our study, the calculation of anatomical-based SYNTAX score for SSII included small ves-
sels of at least 1.5mm and intermediate stenosis causing luminal obstruction of<70%, as
instructed by the SYNTAX trial.[6] However, as recently observed in prospective registries,
intermediate stenosis and small vessels <2.0 mm may not have additive predictive value for
the prognosis of late mortality.[15–17] Hence, SSII calculated when only including severe
Fig 2. Sensitivity and specificity of SSII for the long-term prediction of all-cause mortality.
https://doi.org/10.1371/journal.pone.0200076.g002
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stenosis of>70% in vessels of at least 2 mm, may even more accurately predict late mortality
than currently observed in our study.
Further, the modest reproducibility of the anatomical-based SYNTAX score has to be
acknowledged.[18] However, since our study population with one- or two-vessel disease had a
relatively low angiographic burden, we expected a fair reproducibility of the anatomical-based
SYNTAX score. To assess the reproducibility, a second experienced analyst repeated the ana-
tomical-based SYNTAX score analysis in a representative random sample, blinded for patient
information and previously scored SXscores. Cohen’s kappa was 0.91, which indicated a good
interobserver agreement. Furthermore, since SSII is used in a continuous manner and incor-
porates both anatomical as well as clinical variables, SSII offers higher accuracy than the origi-
nal anatomical-based SYNTAX score.[3]
In addition, our single-center study needs external validation. As expected, the median SSII
score in our population was lower than in the original SSII report and further research is
required to investigate the relation between the actual SSII and corresponding event rate in
one- or two-vessel disease.
Conclusion
This study validates the predictive performance of SSII in patients with one- or two- vessel dis-
ease indicating that, in addition to its known value in patients with left main or three-vessel
disease, SSII may also offer accurate risk prediction in patients with less complex CAD.
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